Table 3.
Incidence of treatment-related adverse events
| AEs | Paclitaxel (n = 38) | Paclitaxel+trametinib (n = 36) | Paclitaxel+pazopanib (n = 37) |
|---|---|---|---|
| n (%) | |||
| Any grade AEs | 36 (95) | 36 (100) | 37 (100) |
| Grade ≥3 AEs | 9 (24) | 27 (75) | 29 (78) |
| Fatal AEs | 0 (0) | 1 (4) | 2 (5) |
| AE per patient for AEs affecting 15 or more patientsa,b | n (n of grade 3 or more) | ||
| Rash | 6 (0) | 35 (14) | 9 (0) |
| ALT increased | 1 (0) | 2 (0) | 12 (9) |
| Fatigue | 19 (1) | 24 (4) | 18 (3) |
| Dyspnoea | 8 (1) | 10 (1) | 8 (2) |
| Abdominal pain | 7 (0) | 11 (1) | 14 (2) |
| Diarrhoea | 17 (0) | 24 (2) | 20 (1) |
| Nausea | 11 (0) | 12 (0) | 16 (1) |
| Anaemia | 3 (0) | 6 (2) | 8 (0) |
| Alopecia | 17 (1) | 13 (0) | 13 (0) |
| Anorexia | 6 (0) | 13 (0) | 11 (0) |
| Constipation | 11 (0) | 13 (0) | 2 (0) |
| Dysgeusia | 3 (0) | 4 (0) | 12 (0) |
| Dyspepsia | 7 (0) | 4 (0) | 4 (0) |
| Epistaxis | 4 (0) | 9 (0) | 6 (0) |
| Headache | 2 (0) | 6 (1) | 7 (0) |
| Vomiting | 6 (0) | 5 (0) | 9 (0) |
| Cough | 8 (0) | 5 (0) | 5 (0) |
a
The AE terms are ranked according to the highest frequency of grade ≥3.
b
In any one row, a patient appears only once whether they had one episode of the AE or many.
AE, adverse events measured by Common Terminology Criteria for Adverse Events V4.03; ALT, alanine aminotransferase; n, number of patients in a group.